Journal article

Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus

Fabien B Vincent, Rangi Kandane-Rathnayake, Rachel Koelmeyer, Alberta Y Hoi, James Harris, Fabienne Mackay, Eric F Morand

Clinical and Translational Immunology | WILEY | Published : 2019


Objectives: To determine the presence and clinical associations of the soluble receptors of B cell-activating factor from the tumor necrosis factor family (BAFF) in serum of patients with systemic lupus erythematosus (SLE). Methods: Serum BAFF and soluble BAFF receptor (sBAFF-R) were quantified using ELISA, and soluble B cell maturation antigen (sBCMA) and transmembrane activator and cyclophilin ligand interactor (sTACI) by Luminex, in 87 SLE patients and 17 healthy controls (HC). Disease activity and organ damage were assessed using SLE Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus International Collaborating Clinics (SLICC) SLE Damage Index (SDI), respectively. Results: BAFF a..

View full abstract

University of Melbourne Researchers


Funding Acknowledgements

The authors warmly thank the patients and healthy subjects for their participation in this study. We also thank the clinical staff of the Lupus Clinic at the Monash Medical Centre, particularly Ms Sue Morton and Mr Andrew Toh. The authors thank the 360biolabs for assistance with the multiplex assays, in particular Ms Devy Santoso. The authors thank the French Society of Rheumatology for its support. FM is recipient of fellowships from the NHMRC of Australia. EFM was supported by the Kim Jolly Lupus Research Trust, and the Monash lupus database has received support from Arthritis and Osteoporosis Victoria, and unrestricted educational grants from GlaxoSmithKline, UCB, AstraZeneca and Eli Lilly Australia. There is no financial support or other benefits from commercial sources for the work reported in the manuscript.